Preimplantation Genetic Testing Market worth $1.2 billion by 2028

Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman’s uterus for a range of genetic problems that can cause implantation failure, miscarriage and birth defects in a resulting child. Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

  • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
  • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
  • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

The report Preimplantation Genetic Testing Market  is projected to reach USD 1.2 billion by 2028 from USD 0.7 billion in 2023, at a CAGR of 11.4% during the forecast period.

The growth of Preimplantation genetic testing market is majorly driven by the high risk of chromosomal abnormalities with advancing maternal age, and the rising number of fertility clinics. Furthermore, the use of fertility treatment options by single parents and same-sex couples is expected to drive the growth of the preimplantation genetic testing market.

Download PDF Brochure: –

Key Growth Drivers:

                    1 Decline in fertility rates      

                    2 Rise of fertility tourism in emerging economies

                    3 Increasing number of fertility clinics and IVF centers

                    4 Increasing public-private investments to develop novel diagnostic techniques.

                    5 High risk of chromosomal abnormalities with advancing maternal age

Market Segmentation: –

Preimplantation genetic screening, or aneuploidy screening, involves screening embryos for the assessment of aneuploidy. This segment is expected to dominate the global preimplantation genetic testing market during the forecast period, driven by a decrease in female fertility with rising maternal age, better implantation rate and reduced IVF cycle times.

By end user, the global preimplantation genetic testing market is broadly segmented into hospitals, diagnostic labs, fertility clinics, and other end users. The large share of this segment can be attributed to factors such as the increasing number of fertility centers globally, the high success rate of treatment in fertility centers, and growing medical tourism in developing countries.

Regional Analysis: –

Based on the region, the preimplantation genetic testing market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American market is driven by high incidence of chromosomal disorders, and an increasing number of awareness programs. Europe is the second-largest market for the preimplantation genetic testing market due to the low fertility rates and increasing maternal age in the region. Asia Pacific will observe high growth during the forecast period with its growing medical tourism for infertility treatment in the region’s countries.

Recent Developments of Preimplantation Genetic Testing Industry

  • In 2023, Thermo Fisher Scientific Inc. (US) launched two new NGS-based test kits to support preimplantation genetic testing-aneuploidy (PGT-A), commonly used in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.
  • In 2022, The Cooper Companies, Inc. (US) released the addition of Parental QC, Genetic PN check, and Origin of Aneuploidy to PGT-A testing as PGT-Complete.
  • In 2021, Vitrolife (Sweden) acquired Igenomix (Spain), a leader in reproductive genetic testing services primarily for IVF clinics.

Request for Sample Pages: –

Top key Players: –

Major players in the preimplantation genetic testing market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Revvity (US), and The Cooper Companies, Inc. (US).